These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 32988967)
1. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967 [TBL] [Abstract][Full Text] [Related]
2. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related]
3. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. Al-Katib AM; Sun Y; Goustin AS; Azmi AS; Chen B; Aboukameel A; Mohammad RM J Hematol Oncol; 2009 Feb; 2():8. PubMed ID: 19220884 [TBL] [Abstract][Full Text] [Related]
4. Design and optimisation of dendrimer-conjugated Bcl-2/x Patterson CM; Balachander SB; Grant I; Pop-Damkov P; Kelly B; McCoull W; Parker J; Giannis M; Hill KJ; Gibbons FD; Hennessy EJ; Kemmitt P; Harmer AR; Gales S; Purbrick S; Redmond S; Skinner M; Graham L; Secrist JP; Schuller AG; Wen S; Adam A; Reimer C; Cidado J; Wild M; Gangl E; Fawell SE; Saeh J; Davies BR; Owen DJ; Ashford MB Commun Biol; 2021 Jan; 4(1):112. PubMed ID: 33495510 [TBL] [Abstract][Full Text] [Related]
5. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D Cells; 2024 Mar; 13(6):. PubMed ID: 38534371 [TBL] [Abstract][Full Text] [Related]
6. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
8. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706 [TBL] [Abstract][Full Text] [Related]
9. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
11. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Lakhani NJ; Rasco D; Wang H; Men L; Liang E; Fu T; Collins MC; Min P; Yin Y; Davids MS; Yang D; Zhai Y Clin Cancer Res; 2024 Feb; 30(3):506-521. PubMed ID: 37971712 [TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia. Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595 [TBL] [Abstract][Full Text] [Related]
13. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331 [TBL] [Abstract][Full Text] [Related]
14. A selective BCL-X Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461 [TBL] [Abstract][Full Text] [Related]
15. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031 [TBL] [Abstract][Full Text] [Related]
16. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252 [TBL] [Abstract][Full Text] [Related]
17. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423 [TBL] [Abstract][Full Text] [Related]
18. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Valentin R; Grabow S; Davids MS Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635 [TBL] [Abstract][Full Text] [Related]
19. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766 [TBL] [Abstract][Full Text] [Related]
20. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]